Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000210538 | SCV000262957 | uncertain significance | Inborn genetic diseases | 2012-11-16 | criteria provided, single submitter | clinical testing | N/AN/ABased on data from the NHLBI Exome Sequencing Project (ESP), the T-allele has an overall frequency of approximately 0.05% (5/10758) total alleles studied. The T-allele was observed in 0.07% (5/7020) European American alleles and was not observed among 3738 African American alleles studied (http://snp.gs.washington.edu/EVS). This amino acid position is poorly conserved in available vertebrate species.This alteration is predicted to be possibly damaging with a score of 0.950 (sensitivity: 0.79; specificity: 0.95)This alteration is predicted to be tolerated with a score of 0.190 (conservation: 1.88) |
Athena Diagnostics | RCV000993304 | SCV001146157 | benign | not provided | 2019-02-06 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001137367 | SCV001297301 | uncertain significance | Spinocerebellar ataxia type 35 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV000993304 | SCV002440048 | benign | not provided | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000993304 | SCV004149764 | likely benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | TGM6: BP4 |
Department of Pathology and Laboratory Medicine, |
RCV000993304 | SCV001549615 | likely benign | not provided | no assertion criteria provided | clinical testing | The TGM6 p.Ser39Cys variant was not identified in the literature nor was it identified in LOVD 3.0. The variant was identified in dbSNP (ID: rs144201778) and ClinVar (classified as uncertain significance by Ambry Genetics). The variant was identified in control databases in 120 of 281364 chromosomes (1 homozygous) at a frequency of 0.0004265 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: South Asian in 23 of 30534 chromosomes (freq: 0.000753), European (non-Finnish) in 93 of 128320 chromosomes (freq: 0.000725), Other in 1 of 7192 chromosomes (freq: 0.000139) and Latino in 3 of 35326 chromosomes (freq: 0.000085), but was not observed in the African, Ashkenazi Jewish, East Asian, or European (Finnish) populations. The p.Ser39 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. | |
Prevention |
RCV003897460 | SCV004722511 | likely benign | TGM6-related disorder | 2020-06-15 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |